Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE versus NIPRIDE.
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE versus NIPRIDE.
HYDRALAZINE HYDROCHLORIDE vs NIPRIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vasodilation of arterioles by direct relaxation of vascular smooth muscle, likely involving interference with calcium movement.
Nipride (sodium nitroprusside) is a potent vasodilator that acts directly on vascular smooth muscle, both arterial and venous, by releasing nitric oxide (NO). Nitric oxide activates guanylate cyclase, increasing cyclic GMP levels, leading to relaxation of smooth muscle and subsequent reduction in peripheral vascular resistance and blood pressure.
Oral: Initiate with 10 mg 4 times daily for 2-4 days, then increase to 25 mg 4 times daily for the remainder of the week, then titrate to 50 mg 4 times daily. Maximum daily dose: 300 mg. Intravenous: 5-20 mg IV bolus, may repeat every 20-30 minutes as needed, or continuous IV infusion 0.5-10 mg/hour.
Intravenous infusion: initial 0.3-0.5 mcg/kg/min, titrate up to 10 mcg/kg/min as needed.
None Documented
None Documented
The terminal elimination half-life of hydralazine is approximately 2–4 hours in patients with normal renal function, but it is prolonged in renal impairment (up to 7–16 hours). The antihypertensive effect often lasts longer than the half-life due to persistent binding to arteriolar receptors.
Nitroprusside: ~2 minutes (converted to cyanide); cyanide (as thiocyanate): 2.7 days; clinical context: continuous IV infusion required; thiocyanate accumulation risk in renal impairment.
Hydralazine is primarily metabolized in the liver via N-acetylation (polymorphic) and hydroxylation. Less than 10% of the dose is excreted unchanged in urine. The major metabolites are hydralazine pyruvic acid hydrazone and other conjugates, which are excreted renally. Fecal elimination is negligible.
Renal: ~50% as unchanged drug; hepatic metabolism to thiocyanate, which is renally eliminated (half-life 2-3 days); <1% fecal.
Category A/B
Category C
Vasodilator
Vasodilator